Heme levels were found to be elevated in osimertinib-resistant EGFR-mutant NSCLC cell lines and in the blood plasma of osimertinib-treated EGFR-mutant NSCLC patients [177]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.